(NASDAQ: XLO) Xilio Therapeutics's forecast annual revenue growth rate of 99.12% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.11%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.33%.
Xilio Therapeutics's revenue in 2025 is $6,344,000.On average, 1 Wall Street analysts forecast XLO's revenue for 2025 to be $3,598,273,332, with the lowest XLO revenue forecast at $3,598,273,332, and the highest XLO revenue forecast at $3,598,273,332. On average, 1 Wall Street analysts forecast XLO's revenue for 2026 to be $4,400,765,945, with the lowest XLO revenue forecast at $4,400,765,945, and the highest XLO revenue forecast at $4,400,765,945.
In 2027, XLO is forecast to generate $2,070,948,680 in revenue, with the lowest revenue forecast at $2,070,948,680 and the highest revenue forecast at $2,070,948,680.